<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33380492</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>356</EndPage><MedlinePgn>349-356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-324306</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Synaptic loss plays a major role in Alzheimer's disease (AD). However so far no neurochemical marker for synaptic loss has been introduced into clinical routine. By mass spectrometry beta-synuclein was established as a candidate marker. We now aimed to set up a novel ELISA for beta-synuclein for evaluation of its potential as a diagnostic and predictive marker for AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analysed in total 393 patients from four specialised centres. The diagnostic groups comprised: AD (n=151), behavioural variant frontotemporal dementia (bvFTD, n=18), Parkinson syndrome (n=46), Creutzfeldt-Jakob disease (CJD, n=23), amyotrophic lateral sclerosis (ALS, n=29), disease control (n=66) and 60 non-neurodegenerative control patients. Results were compared with core AD biomarkers (total tau, phospho-tau and amyloid-&#x3b2; peptide 1-42). Additionally, coexistence of beta-synuclein with vesicular glutamate transporter 1 (VGLUT1) was determined and beta-synuclein levels were quantified in brain homogenates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Beta-synuclein levels quantified with the newly established ELISA correlated strongly with antibody-free quantitative mass spectrometry data (r=0.92 (95% CI: 0.89 to 0.94), p&lt;0.0001). Cerebrospinal fluid (CSF) beta-synuclein levels were increased in AD-mild cognitive impairment (p&lt;0.0001), AD dementia (p&lt;0.0001) and CJD (p&lt;0.0001), but not in bvFTD, Parkinson syndrome or ALS. Furthermore, beta-synuclein was localised in VGLUT1-positive glutamatergic synapses, and its expression was significantly reduced in brain tissue from patients with AD (p&lt;0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We successfully established a sensitive and robust ELISA for the measurement of brain-enriched beta-synuclein, which we could show is localised in glutamatergic synapses. We confirmed previous, mass spectrometry-based observations of increased beta-synuclein levels in CSF of patients with AD and CJD supporting its potential use as a marker of synaptic degeneration.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halbgebauer</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oeckl</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7652-7023</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinacker</LastName><ForeName>Petra</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6697-6522</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmazer-Hanke</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy, Department of Neurology, University of Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderl-Straub</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health Medical Faculty, University of Heidelberg, Mannheim, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Luis Arag&#xe3;o</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Pathology, UZ-Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausner</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatric Psychiatry, Central Institute of Mental Health Medical Faculty, University of Heidelberg, Mannheim, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huss</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3399-9784</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Pathology, UZ-Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Institute of Pathology, Ulm University, Ulm, Baden-W&#xfc;rttemberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6647-5944</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Ulm, Ulm, Baden-W&#xfc;rttemberg, Germany markus.otto@uni-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051846">beta-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Feb;17(2):64</RefSource><PMID Version="1">33432164</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051846" MajorTopicYN="N">beta-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: DRT received speaker honorary or travel reimbursement from Novartis Pharma AG (Switzerland), UCB (Belgium), GE-Healthcare (UK), Biogen (USA); and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK) and Janssen Pharmaceutical Companies (Belgium). MO gave scientific advice for Fujirebio, Roche, Biogen and Axon. The foundation of the state Baden-Wuerttemberg handed in a patent for the measurement of beta-synuclein.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33380492</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-324306</ArticleId><ArticleId IdType="pii">jnnp-2020-324306</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>